
-
Alzamend Neuro NasdaqCM:ALZN Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Location: 3480 Peachtree Road NE, Suite C112c, Atlanta, GA, 30326, United States | Website: https://www.alzamend.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
629.7K
Cash
3.358M
Avg Qtr Burn
-1.827M
Short % of Float
20.29%
Insider Ownership
3.22%
Institutional Own.
0.88%
Qtr Updated
01/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AL001 Details Alzheimer's disease | Phase 2 Data readout | |
AL001 Details Healthy Subjects (Baseline Study) | Phase 2 Data readout | |
AL001 Details Major depressive disorder | Phase 2 Initiation | |
AL001 Details Post-traumatic stress disorder | Phase 2 Initiation | |
AL001 Details Bipolar disease | Phase 2 Initiation | |
ALZN002 Details Alzheimer's disease, Dementia | Phase 1/2 Data readout |